Genus comes in on track

Genus, the global animal genetics company, said its full year figures would be in line with expectations after a good performance over the last two months.

The company said pricing had remained firm, with adjusted operating profit improving in line with expectations despite increasing investment in research and growing its management teams.

Profits had improved strongly in Asia, particularly in Russia and China, and in Latin America, it said.

Start your trial of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

Sign up for MoneyWeek’s free twice-daily newsletter.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Sign up

Going forward, the firm expects strong growth in emerging markets, particularly in China.

The group's businesses in North America also performed well due to cost controls and improved royalty income offsetting softness there.

Europe had performed broadly in line with the prior year, it added.